Dopamine Agonists (Dopamine Agonist)

Subscribe to Selected New Research on Dopamine Agonists

1975 relevant articles (185 outcomes, 232 trials/studies) found for this Bio-Agent

Description: Drugs that bind to and activate dopamine receptors.

Also Known As:

Dopamine Agonist; Agonists, Dopamine Receptor; Agonists, Dopaminergic; Dopamine Receptor Agonist; Dopaminergic Agonist; Receptor Agonists, Dopamine; Agonist, Dopamine; Agonist, Dopamine Receptor; Agonist, Dopaminergic; Agonists, Dopamine; Receptor Agonist, Dopamine; Dopamine Receptor Agonists; Dopaminergic Agonists

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses

Pharmacologic Actions: 49

Molecular Mechanisms of Pharmacological Action: 5

Neurotransmitter Agents: 5405

Dopamine Agents: 379

Dopamine Agonists: 1975

Physiological Effects of Drugs: 1

Neurotransmitter Agents: 5405

Dopamine Agents: 379

Dopamine Agonists: 1975

Experts

1.	Jenner, Peter: 5 articles (12/2007 - 02/2002)
2.	Bonuccelli, Ubaldo: 4 articles (03/2008 - 12/2003)
3.	Chaudhuri, K Ray: 4 articles (03/2007 - 10/2002)
4.	Jankovic, Joseph: 4 articles (09/2007 - 11/2003)
5.	Colao, Annamaria: 4 articles (04/2008 - 06/2002)
6.	Macphee, Graeme: 3 articles (12/2006 - 04/2004)
7.	Reichmann, H: 3 articles (01/2006 - 09/2000)
8.	Stewart, David: 3 articles (12/2006 - 01/2003)
9.	Uitti, Ryan J: 3 articles (12/2006 - 07/2002)
10.	Yamamoto, Mitsutoshi: 3 articles (04/2008 - 10/2006)

Related Diseases

1.	Parkinson Disease (Parkinson's Disease) 01/01/2008 - "Considerable methodological differences in the identified studies complicate a comparison and impede clear evidence as to which dopamine agonist treatment is the most cost effective in early Parkinson's disease" 10/01/2007 - "At present, dopamine agonists play an important role in antiparkinsonian therapy since they were proved effective in the management of both advanced- and early-stage Parkinson's disease" 04/01/1995 - "These findings suggest that combination therapy with a partial D2 agonist and a full D1 agonist or monotherapy with a dopamine agonist that has both partial D2 and full D1 agonist properties might be beneficial for treating motor dysfunction in Parkinson's disease without inducing dopaminergic side effects." 12/01/2003 - "Dopamine agonists are effective in the management of both advanced and early-stage Parkinson's disease" 12/01/2003 - "BACKGROUND: Oral dopamine agonists are effective for treating early Parkinson's disease (PD)" Get all the results and reference details, order at left...
2.	Prolactinoma (Prolactinomas) 05/25/2001 - "In the case of a prolactinoma medical treatment with dopamine receptor agonists is the therapy of choice because it causes rapid tumour shrinkage and symptomatic improvement in most patients, so that irradition of the tumour is not indicated" 01/01/2007 - "Remission rate was very high (90%) among women with microprolactinoma not treated with dopamine agonist before the surgical treatment" 03/28/2003 - "This is relevant because macroprolactinomas with low secretory activity can also be treated successfully with dopamine agonists" 01/01/1995 - "BACKGROUND: In the last decade, the treatment of macroprolactinomas has been significantly improved by the introduction in the clinical practice of new drugs with dopamine-agonist properties" 07/01/2005 - "CONCLUSIONS: This study confirms that abrupt withdrawal of chronic dopamine agonist therapy, following 2 to 3 years of treatment is safe and associated with long-term remission in 30-40% of subjects with microprolactinomas" Get all the results and reference details, order at left...
3.	Neoplasms (Cancer) 05/01/2005 - "Dopamine agonists are effective in the management of PRL-secreting tumors; they cause marked reversible tumor shrinkage in the substantial majority of patients" 08/01/2006 - "Remission was significantly associated with being off of a dopamine agonist at the time of GKRS and a tumor volume less than 3.0 cm3 (P < 0.05 for both)" 01/01/2007 - "While conventional therapies, including dopamine agonists, transsphenoidal surgery and radiotherapy, are usually effective in controlling tumor growth, some patients develop treatment-resistant tumors" 11/01/1999 - "The majority, of PRL-secreting tumors can be effectively treated with dopamine agonists" 09/01/1999 - "In patients with such tumors, a trial of dopamine agonists at high dose may be considered before initiation of more invasive medical treatment." Get all the results and reference details, order at left...
4.	Hyperprolactinemia 01/01/1985 - "The concept of "transient hyperprolactinemia' is analyzed and alternative explanations for the positive results of dopamine agonist therapy in this particular condition are proposed" 07/01/2003 - "A further study on non-operated Ménière's patients presenting hyperprolactinemia and on dopamine agonist treatment, is needed in order to assess the role of stress in Ménière's patients" 06/01/2007 - "Normalization of PRL levels during therapy with dopamine agonists was significantly more frequent in patients with monomeric hyperprolactinemia than in subjects with macroprolactinemia (78.6% vs 32%, P=0.0006)" 07/01/2006 - "We report two children with macroadenomas and hyperprolactinemia resistant to medical therapy using dopamine agonists, who experienced secondary pituitary dysfunction" 12/01/2004 - "Therefore, macroprolactinemia must be ruled out in women presenting with hyperandrogenic symptoms and increased serum PRL concentrations to avoid misdiagnosis (hyperprolactinemia is an exclusion criterion for the diagnosis of PCOS), unnecessary diagnostic tests, and inappropriate use of dopaminergic agonists." Get all the results and reference details, order at left...
5.	Restless Legs Syndrome (Restless Legs) 09/01/2004 - "BACKGROUND: Controlled clinical trials robustly demonstrate the short-term efficacy of dopamine agonists (DA) for restless legs syndrome (RLS), but little is known about the long-term efficacy and long-term adverse events" 12/01/2005 - "Evidence-based and clinical guidelines identify dopamine agonists as a first-line treatment for daily restless legs symptoms, and such substances are in the process of registration for this indication" 09/01/2008 - "STUDY OBJECTIVES: To define which leg movements (LM) associated with restless legs syndrome (RLS) respond to dopamine-agonist treatment and verify if they fall within current diagnostic criteria for periodic LM during sleep (PLMS)" 05/01/2008 - "PURPOSE: We performed a meta-analysis of randomized placebo-controlled trials of nonergot dopamine agonists (NEDAs) for the treatment of restless legs syndrome" 12/01/2005 - "This review discusses treatment studies of dopamine agonists in patients with restless legs syndrome and focuses on long-term treatment with dopamine agonists." Get all the results and reference details, order at left...
301 Diseases and 1975 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Levodopa (L Dopa)
2.	Prolactin
3.	cabergoline
4.	pramipexol (pramipexole)
5.	Bromocriptine (Parlodel)
6.	Pergolide (Permax)
7.	ropinirole (Requip)
8.	Apomorphine
9.	Dopamine (Intropin)
10.	Somatostatin (Somatotropin Release-Inhibiting Factor)
483 Drugs and Important Bio-Agents and 1410 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Self Administration (Administration, Self)
2.	Transplants (Transplant)
3.	Hypophysectomy
4.	Adrenalectomy
5.	Drug Therapy (Chemotherapy)
25 Therapies and Procedures and 42 more articles analyzed in the Research Interface, order at left...

Research Interface Subscription

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Searches
2 clicks from Disease to Drug to Evidence
Trial references
All the Positive Outcomes
Drug and Therapy searches
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface Subscription

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>